Advantage Trust Company’s iShares Biotechnology ETF IBB Stock Holding History

Advantage Trust Company’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$916K	Buy	4,817 +140	+3%	+$24.1K	0.32%	25
2026 Q1	$790K	Hold	4,677	–	–	0.35%	21
2025 Q4	$789K	Hold	4,677	–	–	0.36%	20
2025 Q3	$675K	Sell	4,677 -375	-7%	-$51.2K	0.31%	26
2025 Q2	$639K	Sell	5,052 -86	-2%	-$10.6K	0.31%	27
2025 Q1	$657K	Sell	5,138 -4,220	-45%	-$572K	0.4%	23
2024 Q4	$1.24M	Sell	9,358 -4,344	-32%	-$611K	0.73%	15
2024 Q3	$2M	Buy	13,702 +63	+0.5%	+$9.12K	1.35%	15
2024 Q2	$1.87M	Sell	13,639 -270	-2%	-$36K	1.34%	14
2024 Q1	$1.91M	Sell	13,909 -358	-3%	-$48.9K	1.41%	15
2023 Q4	$1.94M	Buy	+14,267	New	+$1.74M	1.53%	16

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Advantage Trust Company's IBB Position: Q2 2026 in Review

Advantage Trust Company increased its iShares Biotechnology ETF (IBB) stake by 3% in Q2 2026, buying an estimated $24.1K and bringing the position to 4,817 shares worth $916K. The position accounts for 0.32% of the portfolio, ranked #25.

Advantage Trust Company first reported a position in IBB in Q4 2023 and has held it in 11 quarters since. The position peaked at $2M in Q3 2024. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Advantage Trust Company held 4,817 shares of iShares Biotechnology ETF worth $916K as of Q2 2026.
Advantage Trust Company bought 140 iShares Biotechnology ETF shares in Q2 2026, an estimated $24.1K.
iShares Biotechnology ETF made up 0.32% of Advantage Trust Company's portfolio in Q2 2026, its #25 holding.
Advantage Trust Company first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 11 quarters since.
Advantage Trust Company's iShares Biotechnology ETF position peaked at $2M in Q3 2024.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Advantage Trust Company's 13F filing for Q2 2026, filed 17 Jul 2026.